Posted by Michael Wonder on 15 Jan 2024
Santhera receives approval for Agamree (vamorolone) as a treatment for Duchenne muscular dystrophy in the United Kingdom
12 January 2024 - Launches of Agamree in Europe, with Germany taking the lead, are planned to start in Q1, 2024.
Santhera Pharmaceuticals announces that Agamree (vamorolone) has been approved in the United Kingdom for the treatment of Duchenne muscular dystrophy in patients 4 years of age and older, independent of the underlying mutation and ambulatory status.
